Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck & Co.
Biotech
Merck ADC RORs into phase 3 with 100% complete response rate
Merck trumpeted a 100% complete response rate but also reported safety signals that informed the decision to take the low dose into phase 3.
Nick Paul Taylor
Dec 9, 2024 5:03am
Pyxis' shares fall on lukewarm early ADC results in solid tumors
Nov 21, 2024 2:30pm
Biophama VC, deal values and exits all rise in Q3: Pitchbook
Nov 20, 2024 6:15am
Merck pays $588M for bispecific to defend Keytruda’s kingdom
Nov 14, 2024 7:45am
Arcus drops promising data on HIF-2a candidate in kidney cancer
Oct 24, 2024 2:48pm
Merck snaps up preclinical DNA biotech for $1.3B biobucks
Oct 23, 2024 7:05am
